Get the initial IRB submission right the first time.
WCG Randomized 1,600 Participants for RSV Vaccine Trial
October 31st 2024A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
WCG Meets Enrollment 24 Months Early for Top 5 Pharma’s Decentralized Trial
October 31st 2024A sponsor needed to get their Phase II dermatology study enrollment back on track. The study was underway for 11 months across 32 sites globally with only 20 subjects enrolled to date. With WCG support, enrollment was concluded 24 months ahead of schedule.
WCG Support Empowers Oncology Sites to Reach Full Potential
October 31st 2024A top 5 sponsor was falling behind on data entry for their global oncology portfolio, which included 130+ sites and 100+ protocols. WCG supported data entry and query resolution for 130+ sites, resolving data entry backlog in time for interim analyses.
13 Day Decrease in Referral to Randomization Time
October 31st 2024A sponsor’s glaucoma and ocular hypertension studies were behind on enrollment. The sponsor had started an outreach campaign which was not providing the desired results. WCG developed a new recruitment strategy mid-study comprised of a multi-channel outreach campaign.